Other content in this Stream
From enabling the manufacturing of biopharmaceuticals to developing its own drug pipeline.
Prometic announces positive feedback from FDA type-c meeting on Ryplazim (plasminogen) BLA
Implementation plan for additional analytical assays and in-process controls confirmed Company finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing of
Prometic to host key opinion leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for...
Key Opinion Leader meeting, Friday, September 7th in New York City, on a novel treatment for Alström Syndrome (AS).
Prometic to report its second quarter 2018 financial results and hold conference call / webcast
Annual Information Form 2017
Prometic Annual Information Form 2017
Quarterly Report Q2 2018
Quarterly Report Q1 2018
Prometic reports its 2018 first quarter highlights and financial results
Corporate Governance and Nominating Committee Charter 2017
Board of Directors Charter 2017
Chairman Mandate 2018
Code of Ethics and Business Conduct 2017
Full detailed breakdown of Prometics Code of Ethics and Business Conduct for 2017 including details on regulatory compliance.
Virtual Tour of Prometic Life Science's Manufacturing Process
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment